Catalogue


Future research needs to reduce the risk of primary breast cancer in women [electronic resource] : identification of future research needs from Comparative effectiveness review no. 17 /
prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Oregon Evidence-based Practice Center ; investigators, Jeanne-Marie Guise ... [et al.].
imprint
Rockville, MD : Agency for Healthcare Research and Quality, [2010]
description
1 online resource (1 PDF file (1 v. (various pagings)))
format(s)
Book
Holdings
More Details
added author
imprint
Rockville, MD : Agency for Healthcare Research and Quality, [2010]
restrictions
Licensed for access by U. of T. users.
general note
"September 2010."
Title from PDF t.p.
abstract
The 2009 comparative effectiveness review (CER) on the effectiveness of medications to reduce the risk of primary breast cancer in women without preexisting cancer demonstrated the efficacy of two SERMs, tamoxifen citrate (RR, 0.70; 95% CI, 0.59 to 0.82; 4 trials) and raloxifene (RR, 0.44; CI, 0.27 to 0.71; 2 trials). However, the CER also outlined many adverse effects and unknowns about the medications. The objective of this pilot project was to engage stakeholders to develop and prioritize a list of research questions to address the research gaps related to the CER. First, the goal was to provide sufficient detail--including population, intervention, comparator, and outcome (PICO)--for researchers and funders to use in the development of research proposals and solicitations, respectively. Second, this project was intended to identify a feasible and effective approach to identify and prioritize future research from systematic reviews in general.
catalogue key
9065147
technical details
Mode of access: Internet.
 
Contract No. 290-2007-10057-I
Includes bibliographical references.

  link to old catalogue

Report a problem